Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 3257 - 3264 of 12089 results
What Recession? Big Boston Law Firms Earned Massive Profits in 2020
April 23, 2021| News
Patent Owner Tip #3 for Surviving An Instituted IPR: How Patent Owner Experts Go from Zero to Hero
April 22, 2021| Blog| Viewpoint
Little Known Rule Provides Immigration Path for Foreign Entrepreneurs
April 22, 2021| News
Department of Labor Issues Model COBRA Subsidy Notices and FAQs
April 22, 2021| Blog| Viewpoint
Pass the Salt: DOJ Requires Stone Canyon to Divest Its Evaporated Salt Business to Obtain Merger Clearance
April 22, 2021| Blog| Viewpoint
The International Entrepreneur Parole Rule: A Beacon of Hope for Foreign Entrepreneurs
April 22, 2021| Article| Viewpoint
Developing A Strategic Plan For AI In The Workplace: Where To Start
April 22, 2021| News
The Federal Circuit Provides New Guidance for Patent Licensees Wishing to Challenge the Licensed Patent’s Validity
April 21, 2021| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|